Somatrogon - Wikipedia
网页Somatrogon, sold under the brand name Ngenla, is a medication for the treatment of growth hormone deficiency. [1] [6] [8] Somatrogon is a glycosylated protein constructed from human growth hormone and a small part of human chorionic gonadotropin which is appended to both the N-terminal and C-terminal. [8] Somatrogon is …
Somatrogon: Uses, Interactions, Mechanism of Action - DrugBank …
网页2019年5月20日 · Somatrogon is a long-acting recombinant human growth hormone used as the long-term treatment of pediatric patients who have growth failure due to growth hormone deficiency.
Somatrogon: First Approval - PubMed
网页Somatrogon (NGENLA ®), a long-acting human growth hormone based on C-terminal peptide technology, is in development by Pfizer and OPKO Health for the treatment of growth hormone deficiency in pediatric and adult patients. Administered as a once-weekly subcutaneous injection, somatrogon reduces treatment burden relative to once-daily human ...
Somatrogon (Ngenla) - NCBI Bookshelf - National Center for ...
网页Somatrogon is a modified long-acting analogue of human growth hormone (GH) and a new molecular entity with receptor binding properties and a mechanism of action analogous to human GH.
Clinical Review - Somatrogon (Ngenla) - NCBI Bookshelf
网页Somatrogon is a modified long-acting analogue of human growth hormone (hGH). It is a new molecular entity with receptor-binding properties and a mechanism of action analogous to hGH. 10 Somatrogon binds to the GH receptor and initiates a signal transduction cascade, culminating in changes in growth and metabolism.
Somatrogon: First Approval | Drugs - Springer
网页2022年1月18日 · Somatrogon, a glycoprotein produced in Chinese Hamster Ovary cells via recombinant DNA technology, consists of the human growth hormone amino acid sequence with one copy of the C-terminal peptide (CTP) derived from human chorionic gonadotropin at the N-terminus and two copies of CTP at the C-terminus [2].
Somatrogon - PubChem
网页Somatrogon is a hormone replacement therapy that aims to restore deficient levels of growth hormone (GH). Like endogenous growth hormone, somatrogon binds to the GH receptor, which leads to the binding of JAK2 to GH receptor and activation of JAK2.
网页Somatrogon (NGENLA ®), a long-acting human growth hormone based on C-terminal peptide technology, is in development by Pzer and OPKO Health for the treatment of growth hormone deciency in pediatric and adult patients.
Somatrogon for growth hormone deficiency - PMC - National …
网页2022年9月1日 · Somatrogon contains the amino acid sequence of growth hormone plus three copies of the C-terminal peptide of human chorionic gonadotropin. The C-terminal modification extends the half-life of growth hormone to approximately 28 hours. Somatrogon will remain in circulation for six days, so weekly subcutaneous dosing is possible.
Somatrogon in paediatric growth hormone deficiency: a profile of …
网页2022年11月18日 · Somatrogon (NGENLA ®), a modified long-acting form of recombinant human growth hormone (rhGH), is a valuable new option for the treatment of paediatric patients aged ≥ 3 years with growth disturbance due to insufficient GH secretion in the EU, and offers the convenience of once-weekly administration.